Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

Last updated: April 23, 2020
Sponsor: Chinese Academy of Medical Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04158505
HR-BLTN-016
  • Ages > 18
  • All Genders

Study Summary

This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. ≥18 years old with histologically confirmed HER2 positive breast cancer.

  2. Documented HER2 overexpression by local laboratory ,defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) positive.

  3. Physician has determined that treatment with pyrotinib is indicated.

  4. Traceable medical record available.

Exclusion

Exclusion Criteria:

  1. Patients who are unable to understand the nature of the study and are unwilling tosign an informed consent .

  2. Pregnant or breast feeding patients

  3. Patients participating in any interventional clinical trial that includesinvestigational or marketed products at the time of enrollment.

  4. Patients not suitable for this study under investigators' consideration.

Study Design

Total Participants: 3000
Study Start date:
February 28, 2020
Estimated Completion Date:
November 15, 2023

Connect with a study center

  • National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing 100021
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.